Amedisys, Inc. (NASDAQ:AMED) Shares Sold by Olympiad Research LP

Olympiad Research LP trimmed its stake in shares of Amedisys, Inc. (NASDAQ:AMED) by 72.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,865 shares of the health services provider’s stock after selling 15,077 shares during the period. Olympiad Research LP’s holdings in Amedisys were worth $532,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. Westchester Capital Management LLC raised its position in shares of Amedisys by 9.5% during the 3rd quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock worth $107,976,000 after purchasing an additional 97,476 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Amedisys by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after purchasing an additional 7,071 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of Amedisys by 11,621.9% during the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after purchasing an additional 553,435 shares during the last quarter. Calamos Advisors LLC raised its position in shares of Amedisys by 22.7% during the 4th quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider’s stock worth $44,255,000 after purchasing an additional 90,097 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Amedisys by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock worth $33,400,000 after purchasing an additional 9,004 shares during the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a report on Wednesday, February 12th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $100.75.

Amedisys Price Performance

Shares of NASDAQ:AMED opened at $90.43 on Friday. The company has a market cap of $2.96 billion, a P/E ratio of 35.88, a P/E/G ratio of 1.80 and a beta of 0.73. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The business has a fifty day simple moving average of $90.74 and a 200-day simple moving average of $93.40.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.